Company is working to redefine epilepsy with proven treatment
options, healthy living initiatives and community education
LONDON--(BUSINESS WIRE)--Nov. 1, 2017--
LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a
market-leading medical technology company, today recognizes November as
National Epilepsy Awareness Month in the United States. The Company is
working to bring greater attention to epilepsy, which is the fourth most
common neurological disorder affecting more than 65 million people
worldwide. According to the U.S. Centers for Disease Control and
Prevention, there are 3.4 million people with epilepsy in the United
States; this number is greater than ever before. The need for awareness,
treatment options and education is at an all-time high.
One in three patients with epilepsy has the type that is not well
controlled with medication, called drug-resistant epilepsy. For those
patients, prescribing more medicine is usually not an effective option.
There are a variety of wellness activities patients might consider
adding to their treatment regimen to help with seizure control,
including:
-
Improved nutrition – Special diets and natural, whole food diets may
result in improved seizure control.
-
Increased fitness – Exercise has been shown to improve seizure control
and overall well-being.
-
Reduced stress – A recent study of those with drug-resistant epilepsy
stated stress is the most commonly reported seizure trigger.1
“At LivaNova, we believe every month is epilepsy awareness month.
However, during the month of November, we turn up the volume to help
raise awareness of this potentially devastating disorder and the
available treatment options,” said Jason Richey, LivaNova’s President of
North America and General Manager of the Neuromodulation business
franchise. “We’ve offered our Vagus
Nerve Stimulation® (“VNS Therapy”) System, an
FDA-approved treatment for drug-resistant epilepsy, for 20 years now in
the United States and even longer worldwide. We are committed to
offering proven results for adults and children as young as four years
old and to developing smarter technology, like our latest VNS Therapy
System, which includes the SenTiva™ generator and the Next Generation
Programming System.”
This November, LivaNova is kicking off a campaign, Redefine Epilepsy,
to increase epilepsy awareness via a cross-channel digital, social and
local campaign to promote disease-state education and wellness tips. Redefine
Epilepsy invites the community to share stories of awareness,
wellness activities and education. VNS
Therapy for Epilepsy on Facebook will feature the community’s
stories, as well as highlight its own tips and awareness activities
throughout Epilepsy Awareness Month.
1 Nakken, KO et al.Epilepsy & Behavior 6(2005)85-89.
About VNS Therapy for Epilepsy
VNS Therapy is the first and only FDA-approved device for drug-resistant
epilepsy that is clinically proven safe and effective for adults and
children as young as four years of age. VNS Therapy is designed to
prevent seizures before they occur and stop them if they do. It is a
unique treatment approach developed specifically for people with
drug-resistant epilepsy — a condition that affects one in three people
with epilepsy. For more information, visit VNSTherapy.com
or SeizureControl.com.
INTENDED USE/INDICATIONS – UNITED STATES
The VNS Therapy System is indicated for use as an adjunctive therapy in
reducing the frequency of seizures in patients four years of age and
older with partial onset seizures that are refractory to antiepileptic
medications.
Individual results may vary. Common side effects include hoarseness or
changes in voice tone, prickling feeling in the skin, shortness of
breath, sore throat and coughing. Visit www.VNSTherapy.com/important-safety-information
to view safety and full prescribing information.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova’s advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London and with a presence in more than 100 countries worldwide, the
company employs more than 4,500 employees. LivaNova operates as three
business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm
Management, with operating headquarters in Mirandola
(Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.livanova.com.
Safe Harbor Statement
Any forward-looking statements are subject to risks and uncertainties
such as those described in LivaNova’s periodic reports on file with the
Securities and Exchange Commission. Actual results may differ materially
from anticipated results.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005302/en/
Source: LivaNova PLC
LivaNova PLC Investor Relations and Media
Karen King, +1-281-228-7262
Vice
President, Investor Relations & Corporate Communications
or
Deanna
Wilke, +1-281-727-2764
Corporate External Communications Manager
corporate.communications@livanova.com
or
Havas
PR
Melissa Rieger, +1-412-251-2172
melissa.rieger@havas.com